Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEDERA early versus delayed etanercept in early rheumatoid arthritis
2010-023910-30Phase 4Completed
- Sponsor
- University of Leeds
- Start
- Feb 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of etanercept in rheumatoid arthritis (RA) (2 arms), sponsored by University of Leeds. Primary endpoints: Clinical remission at 48 weeks and Definition of clinical remission. Started Feb 2011; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-023910-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023910-30.